{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:48:56Z","timestamp":1760550536105,"version":"3.44.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1053\/j.seminhematol.2018.04.005","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T13:17:55Z","timestamp":1523971075000},"page":"215-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms"],"prefix":"10.1053","volume":"55","author":[{"given":"S\u00e9rgio","family":"Ferreira Cristina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Polo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o F.","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1053\/j.seminhematol.2018.04.005_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib2","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4065\/78.2.174","article-title":"Polycythemia vera: a comprehensive review and clinical recommendations","volume":"78","author":"Tefferi","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"13","key":"10.1053\/j.seminhematol.2018.04.005_bib4","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib5","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00277-014-2205-y","article-title":"Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options","volume":"93","author":"Stein","year":"2014","journal-title":"Ann Hematol"},{"issue":"17","key":"10.1053\/j.seminhematol.2018.04.005_bib6","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib7","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"16","key":"10.1053\/j.seminhematol.2018.04.005_bib8","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"7037","key":"10.1053\/j.seminhematol.2018.04.005_bib9","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"24","key":"10.1053\/j.seminhematol.2018.04.005_bib10","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/01.moh.0000154029.05396.d2","article-title":"Polycythemia vera and other primary polycythemias","volume":"12","author":"Prchal","year":"2005","journal-title":"Curr Opin Hematol"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1750-1172-2-3","article-title":"Essential thrombocythemia","volume":"2","author":"Bri\u00e8re","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2006-939430","article-title":"Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia","volume":"32","author":"Johansson","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"17","key":"10.1053\/j.seminhematol.2018.04.005_bib14","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"New Eng J Med"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib15","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1200\/JCO.2004.00.9316","article-title":"Pathogenesis of myelofibrosis with myeloid metaplasia","volume":"23","author":"Tefferi","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2018.04.005_bib16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib17","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.exphem.2009.07.005","article-title":"JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis","volume":"37","author":"Hussein","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ajh.20721","article-title":"Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera","volume":"82","author":"Ganly","year":"2007","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2018.04.005_bib19","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/ajh.22058","article-title":"Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis","volume":"86","author":"Pardanani","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib20","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.3324\/haematol.2014.115113","article-title":"JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms","volume":"100","author":"Shirane","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"10.1053\/j.seminhematol.2018.04.005_bib21","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","article-title":"The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera","volume":"108","author":"Lippert","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Eng J Med"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3343\/alm.2012.32.6.385","article-title":"Correlations between janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms","volume":"32","author":"Ha","year":"2012","journal-title":"Ann Lab Med"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib24","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/ajh.20872","article-title":"Analysis of JAK2 V617F mutation in Chinese patients with myeloproliferative disorders","volume":"82","author":"Chen","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib25","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3892\/ol.2014.2801","article-title":"Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms","volume":"9","author":"Zhang","year":"2015","journal-title":"Oncol Lett"},{"issue":"6","key":"10.1053\/j.seminhematol.2018.04.005_bib26","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ajh.23694","article-title":"Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2018.04.005_bib27","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3324\/haematol.2012.064683","article-title":"Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow","volume":"97","author":"Schnittger","year":"2012","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3343\/alm.2015.35.1.22","article-title":"Calreticulin exon 9 mutations in myeloproliferative neoplasms","volume":"35","author":"Ha","year":"2015","journal-title":"Ann Lab Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2018.04.005_bib29","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bcmd.2015.07.005","article-title":"CALR mutations screening in wild type JAK2 V617F and MPL W515K\/L Brazilian myeloproliferative neoplasm patients","volume":"55","author":"Nunes","year":"2015","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"10.1053\/j.seminhematol.2018.04.005_bib30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/bjh.13076","article-title":"CALR versus JAK2 mutated essential thrombocythaemia\u2014a report on 141 patients","volume":"168","author":"Trifa","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.leukres.2009.06.017","article-title":"JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms","volume":"34","author":"Siemi\u0105tkowska","year":"2010","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib32","first-page":"474","article-title":"JAK2 V617F and MPL W515L\/K mutations in korean patients with essential thrombocythemia","volume":"30","author":"Kim","year":"2010","journal-title":"Korean J Lab Med"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib33","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.patbio.2009.06.005","article-title":"JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects","volume":"59","author":"Benmoussa","year":"2011","journal-title":"Pathol Biol"},{"issue":"10","key":"10.1053\/j.seminhematol.2018.04.005_bib34","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1726-4901(10)70115-5","article-title":"Prevalence of MPL W515L\/K mutations in Taiwanese patients with philadelphia-negative chronic myeloproliferative neoplasms","volume":"73","author":"Lieu","year":"2010","journal-title":"J Chin Med Assoc"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib35","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1445-5994.2007.01589.x","article-title":"Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders","volume":"38","author":"Lieu","year":"2008","journal-title":"Intern Med J"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-014-0048-6","article-title":"The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"7","author":"Wu","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1309\/AJCPALP51XDIXDDV","article-title":"The prevalence of JAK2, MPL, and CALR mutations in Chinese patients with BCR-ABL1-negative myeloproliferative neoplasms","volume":"144","author":"Lin","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1309\/AJCPUAAC16LIWZMM","article-title":"CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms","volume":"143","author":"Kim","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib39","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W L\/K mutation in essential thrombocythemia","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib40","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","article-title":"Clinical implications of the JAK2 V617F mutation in essential thrombocythemia","volume":"19","author":"Antonioli","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib41","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.leukres.2006.09.005","article-title":"Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders","volume":"31","author":"Speletas","year":"2007","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergencyto.2009.10.014","article-title":"Distinct patterns of cytogenetics and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations","volume":"197","author":"Millecker","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib43","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s00277-014-2151-8","article-title":"Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia","volume":"93","author":"Chen","year":"2014","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2018.04.005_bib44","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00277-009-0788-5","article-title":"Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation","volume":"89","author":"Stefano","year":"2010","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2018.04.005_bib46","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11670-012-0072-4","article-title":"JAK2 V617F, MPL W515L and JAK2 Exon 12 Mutations in Chinese Patients with Primary Myelofibrosis","volume":"24","author":"Xia","year":"2012","journal-title":"Chin J Cancer Res"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib47","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4274\/tjh.65807","article-title":"MPL W515L\/K mutations in chronic myeloproliferative neoplasms","volume":"30","author":"Akp\u0131nar","year":"2013","journal-title":"Turk J Hematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2018.04.005_bib48","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3324\/haematol.2014.109249","article-title":"Calreticulin mutations in Chinese with primary myelofibrosis","volume":"99","author":"Li","year":"2014","journal-title":"Haematologica"},{"issue":"7","key":"10.1053\/j.seminhematol.2018.04.005_bib49","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib50","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.3324\/haematol.2014.109199","article-title":"Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients","volume":"99","author":"Qiao","year":"2014","journal-title":"Haematologica"},{"issue":"6","key":"10.1053\/j.seminhematol.2018.04.005_bib51","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5581\/1516-8484.20110116","article-title":"Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia","volume":"33","author":"Santos","year":"2011","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib52","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib53","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib54","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1365-2141.2008.07223.x","article-title":"Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients","volume":"142","author":"Kouropi","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib55","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib56","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3324\/haematol.13223","article-title":"Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera","volume":"94","author":"Schnittger","year":"2009","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib57","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1309\/AJCPK7KGOWPHYWM0","article-title":"High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera","volume":"134","author":"Yeh","year":"2010","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1053\/j.seminhematol.2018.04.005_bib58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2353\/jmoldx.2009.080114","article-title":"Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias","volume":"11","author":"Ma","year":"2009","journal-title":"J Mol Diagn"},{"issue":"3","key":"10.1053\/j.seminhematol.2018.04.005_bib59","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib60","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F mediated transformation","volume":"102","author":"Lu","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1053\/j.seminhematol.2018.04.005_bib61","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2018.04.005_bib62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.hemonc.2014.12.002","article-title":"The mutation profiles of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"8","author":"Labastida-Mercado","year":"2015","journal-title":"Hematol Oncol Stem Ther"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib63","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib64","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2141.2010.08083.x","article-title":"Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis","volume":"149","author":"Boyd","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bcmd.2011.04.004","article-title":"Detection of MPL exon 10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms","volume":"47","author":"Chen","year":"2011","journal-title":"Blood Cells Mol Dis"},{"issue":"7","key":"10.1053\/j.seminhematol.2018.04.005_bib66","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3324\/haematol.2014.118299","article-title":"Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations","volume":"100","author":"Assaf","year":"2015","journal-title":"Haematologica"},{"issue":"21","key":"10.1053\/j.seminhematol.2018.04.005_bib67","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1182\/blood-2013-02-486050","article-title":"Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms","volume":"121","author":"Rumi","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib68","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib69","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2018.04.005_bib70","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","article-title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","volume":"127","author":"Araki","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2018.04.005_bib71","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.leukres.2015.02.006","article-title":"Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2V617F or MPL mutations","volume":"39","author":"Li","year":"2015","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib72","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","article-title":"Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia","volume":"145","author":"Gelsi-Boyer","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib73","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/leu.2009.141","article-title":"Mutations of ASXL1 gene in myeloproliferative neoplasms","volume":"23","author":"Carbuccia","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib74","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/gcc.21960","article-title":"Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms","volume":"51","author":"Brecqueville","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib75","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/JBM.S78826","article-title":"Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms","volume":"6","author":"Yonal-Hindilerden","year":"2015","journal-title":"J Blood Med"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib76","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib77","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutations of TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib78","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2018.04.005_bib79","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Eng J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2018.04.005_bib80","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/ajh.23703","article-title":"Primary myelofibrosis: 2014 update on diagnosis, risk-stratification and management","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1053\/j.seminhematol.2018.04.005_bib81","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2018.04.005_bib82","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2018.04.005_bib83","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2005-05-2087","article-title":"The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders","volume":"106","author":"Scott","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib84","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.12099","article-title":"Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population","volume":"160","author":"Nielsen","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib85","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5045\/br.2013.48.2.128","article-title":"The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasm","volume":"48","author":"Park","year":"2013","journal-title":"Blood Res"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib86","doi-asserted-by":"crossref","DOI":"10.1007\/s11899-017-0411-0","article-title":"Molecular pathogenesis of myeloproliferative neoplasms: influence of age and gender","author":"Patterson-Fortin","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib87","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib88","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1007\/s11033-014-3559-x","article-title":"Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis","volume":"41","author":"Cetin","year":"2014","journal-title":"Mol Bio Rep"},{"issue":"3","key":"10.1053\/j.seminhematol.2018.04.005_bib89","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2018.04.005_bib90","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"issue":"9","key":"10.1053\/j.seminhematol.2018.04.005_bib91","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2018.04.005_bib92","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.11653","article-title":"Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia","volume":"93","author":"Antonioli","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib93","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","article-title":"Anaemia characterises patients with myelofibrosis harbouring MPLW515L\/K mutation","volume":"137","author":"Guglielmelli","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib94","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3343\/alm.2015.35.2.233","article-title":"Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea","volume":"35","author":"Park","year":"2015","journal-title":"Ann Lab Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2018.04.005_bib95","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Alvarez-Larr\u00e1n","year":"2016","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2018.04.005_bib96","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib97","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib98","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2018.04.005_bib99","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","article-title":"Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation","volume":"23","author":"Kr\u00f6ger","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1053\/j.seminhematol.2018.04.005_bib100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2018.04.005_bib101","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review","volume":"124","author":"Lussana","year":"2009","journal-title":"Thromb Res"},{"issue":"9","key":"10.1053\/j.seminhematol.2018.04.005_bib102","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3324\/haematol.12970","article-title":"Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain","volume":"93","author":"Ziakas","year":"2008","journal-title":"Haematologica"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196317301695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196317301695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:25:51Z","timestamp":1758522351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196317301695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0037196317301695"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2018.04.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2018.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}